Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 90

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 90
---
 cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our common stock, or provide more favorable relative recommendations about our competitors, our share price would likely decline.
If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in
the financial markets, which in turn could negatively impact our share price or trading volume.

Sales
of a substantial number of our shares in the public market by our existing shareholders could cause our share price to decline.

Sales
of a substantial number of our shares in the public market or the perception that these sales might occur, could depress the market price
of our securities and could impair our ability to raise capital through the sale of additional equity securities. We are not able to
predict the effect that sales may have on the prevailing market price of our securities.

We
are a “smaller reporting company” and the reduced disclosure requirements applicable to smaller reporting companies may make
our common stock less attractive to investors.

We
are considered a “smaller reporting company.” We are therefore entitled to rely on certain reduced disclosure requirements,
such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures
in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations
and financial prospects. We cannot predict whether investors will find our common stock less attractive because we may rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock prices may be more volatile.

Maintaining
and improving our financial controls and the requirements of being a public company may strain our resources, divert management’s
attention and affect our ability to attract and retain qualified board members.

As
a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley
Act and The Nasdaq Stock Market LLC (“Nasdaq”) rules. The requirements of these rules and regulations increase our legal
and financial compliance costs, make some activities more difficult, time-consuming or costly and place strain on our personnel, systems
and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our
business and financial condition.

59

The
Sarbanes-Oxley Act